We are focused on developing disease-modifying therapies that address unmet medical needs of patients and families suffering from rare diseases with the goal of making a positive difference in their lives.
Matthew Gantz, President and Chief Executive Officer
Courtesy of debra—The Dystrophic Epidermolysis Bullosa Research Association of America and the Oliveira family. Used with permission.
RDEB is a devastating, rare genetic blistering disease with no FDA-approved treatments currently available
Read MoreFDA Awards 11 Grants to Clinical Trials to Develop New Medical Products for Rare Disease Treatments
Read MoreResearch to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome, debilitating disorders with no FDA-approved treatments
Read MoreLife sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial
Read More